about
Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysisThe frequency of 'atypia of undetermined significance' interpretations for thyroid fine-needle aspirations is negatively correlated with histologically proven malignant outcomesDetection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.Molecular markers: Implications for cytopathology and specimen collectionBrain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma.Thematic review series: the immune system and atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in atherosclerosis.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.The immune system and murine atherosclerosis.Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathologyVLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice.Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio: a proposed performance measure for reporting in The Bethesda System for thyroid cytopathology.Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): an overview and update for the cytopathologist.Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review."Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines.Measurement Bias of Gross Pathologic Compared With Radiologic Tumor Size of Resected Lung Adenocarcinomas: Implications for the T-Stage Revisions in the Eighth Edition of the American Joint Committee on Cancer Staging Manual.Fine-needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities.EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology Correlation.Osseous and chondromatous metaplasia in calcific aortic valve stenosis.A case of hypercalcemia secondary to hot tub lung.Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach?Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size.Software-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography.Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT.Tumor biomarker testing in non-small-cell lung cancer: A decade of change.Natural killer T cells in lipoprotein metabolism and atherosclerosis.De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
P50
Q26784085-DDCC2DBD-0866-4FE3-ABDA-49B0A479ED54Q26823254-5DCE825B-3039-4047-9326-04301412D87AQ27853157-A126560C-F2C8-4A9C-BEDB-0CC74C3D9C7BQ28087155-3973E054-7CBD-464A-A3A8-052366D6447DQ35164218-A83B10F3-EE0B-49CC-8322-B86F861CC6AEQ35164473-E4827AB5-4052-4669-8FE2-B4B7B98EECABQ35170413-61B619EE-0CB0-466F-A8EF-F9A0C35952A7Q35175264-ECFC132F-3E9C-411F-8054-B691C9FD93AFQ36072740-5B1FAE72-3D94-40D7-B59E-D62F358F2355Q36114660-A1690501-1D5E-4ACC-A7F8-53900D56B98EQ36256870-6EE55810-838E-4614-8B92-78ABF6137513Q36301400-A4015BC1-D936-497A-9D99-8402CA7D227CQ36493522-39618E69-302A-43B3-B453-AEC4A65C93ACQ37065941-F9CD2D0A-617F-4731-A91B-7075FBE79F24Q37086149-E8255109-6D60-4C82-9FB7-DDAAD81DDC45Q37089091-6EA9007A-8350-4E2E-944D-E906D1879E35Q37238254-0B6402AC-610B-4479-B1FA-E10822ADC78CQ37238413-28D594F4-34CE-4934-B69A-BB0BA49AF507Q37555387-0EBF8CF1-5E36-4FC0-864E-28DF800341B7Q37638241-B951C51B-4239-4A94-BA30-E7F1F956BDE8Q37932472-EF64E9AD-DACB-41A5-8ED5-C1779FE8D4BAQ38206743-45FABC28-954E-4C68-974A-FF9CFCDD938BQ38401764-889C473A-960B-4410-A83D-44A6BC952125Q38441535-D3C8001A-8C69-486F-9DDB-FB52E8BCFB7EQ38699544-818415FE-DC7A-4BCC-AD9B-953211EC238CQ38748502-F94B6D8A-B7F0-43CD-9211-095371286368Q38835217-D20C7496-6C21-4C29-BB9D-2534FA444FFAQ38887117-8486CE56-82D2-45A7-953B-9116A6BC6544Q38937135-1FE2D9A0-F733-4226-B566-C4105889789FQ39159692-86E7D6B5-93B9-4D3D-A8E5-9E3088E9C693Q41343322-3B67F3E6-EB04-4C83-9580-42A94C2AE2F9Q41632839-47E493CD-C3B9-4BA4-917C-323410A21A3CQ43919785-E6091910-EBA8-4543-A527-3EBA567F9DC0Q46857635-03F40953-420E-41F6-B896-8EA5C689C1A0Q47208659-02667CB5-7D9B-4AAA-9E58-B2F68CFBBC4FQ49403336-EFE5124E-EE6E-487A-B37C-0AE294534BB7Q49524293-5441D649-20DA-4485-8794-896D17E17CC0Q50139910-E45CF140-D3B0-4005-BC0D-EA0EF7B75D77Q50190286-E69C2A7E-A334-4328-933E-4222165EB159Q50223674-81E9435C-76F4-4EA2-BDD6-E43B7D39299C
P50
description
researcher ORCID ID = 0000-0002-7234-5652
@en
wetenschapper
@nl
name
Paul A VanderLaan
@ast
Paul A VanderLaan
@en
Paul A VanderLaan
@nl
type
label
Paul A VanderLaan
@ast
Paul A VanderLaan
@en
Paul A VanderLaan
@nl
prefLabel
Paul A VanderLaan
@ast
Paul A VanderLaan
@en
Paul A VanderLaan
@nl
P106
P31
P496
0000-0002-7234-5652